MEI Pharma
Committed to the development of novel, best-in-class, cancer therapies intended to provide improved outcomes to patients
121 employees · est. 2000 · San Diego, United States
MEI Pharma is the older company (2000 vs 2003).
Side-by-Side Comparison
| Metric | MEI Pharma | Portola Pharmaceuticals |
|---|---|---|
| Founded | ||
| Founded | 2000 older | 2003 |
| Headquarters | ||
| Headquarters | San Diego, United States | South San Francisco, United States |
| Employees | ||
| Employees | 121 | 54 |
| Industry | ||
| Industry | Biopharma, Biotechnology | Biopharma, Biotechnology, Health and Wellness |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $160.36M | $1.31B |
| Funding Rounds | ||
| Funding Rounds | 5 | 11 |
| Services | ||
| Services | Not tracked yet | Research and Development in Rare Diseases, Clinical Trials Design and Execution, Patient-Centric Support Programs, Diagnostics Innovation, Business Development Partnerships, Discovery Partnerships |
| Target Customers | ||
| Target Customers | Not tracked yet | Patients with Rare Diseases, Healthcare Providers in Rare Disease, Biopharmaceutical Partners, Regulatory Agencies, Medical Community Focused on Rare Disorders |
| Taxonomy | ||
| Taxonomy | Oncology Company, Clinical-stage Pharmaceutical Company, Novel Cancer Therapies, B-cell Malignancies, Hematologic Malignancies, Solid Tumors, Drug Development, Clinical Trials, HDAC Inhibitor, Histone Deacetylase Inhibitor, Mitochondrial Inhibitor, CDK9 Inhibitor, ME-401, Pracinostat, ME-344 | Biopharmaceutical, Cardiovascular Diseases, Autoimmune Diseases, Thrombosis, Hematologic Disorders, Factor Xa Inhibitor, Acute Coronary Syndrome, Deep Vein Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Myocardial Infarction, Stroke Prevention, SYK/JAK Inhibitor, Oncology, Chronic Inflammatory Diseases |
| Website | ||
| Website | meipharma.com | portola.com |
About MEI Pharma
MEI Pharma, a San Diego-based clinical-stage pharmaceutical company, is dedicated to developing and commercializing novel, best-in-class cancer therapies with the aim of improving patient outcomes. The company's approach involves understanding and leveraging the mechanisms and properties of its drug...
About Portola Pharmaceuticals
Portola Pharmaceuticals, founded in 2003 and headquartered in the United States, operates at the forefront of the biopharma and biotechnology sectors. Specializing in the discovery, development, and commercialization of novel therapeutics, the company is making significant strides in treating thromb...
We will tell you when either one moves
BounceWatch watches MEI Pharma and Portola Pharmaceuticals for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at MEI Pharma and Portola Pharmaceutical... — by email.
Frequently Asked Questions
Compare MEI Pharma with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at MEI Pharma on 12 Sep 2024, and Portola Pharmaceuticals on 12 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
